Trials Sponsors Conditions Drugs Pricing

Conditions

AMH Follicle Cyst Hypogonadism, Hypogonadotropic

Outcome Measures

Primary Outcomes (2)

AMH
Evaluation of a complete hormone profile including AMH in women with HH
2 months
antral follicle count
Evaluation of the antral follicle count in women with HH
2 months

Secondary Outcomes (2)

AMH after 2 months
2 months
Antral follicle count after 2 months
2 months

Interventions

Blood sampleDiagnostic test

Blood samples were taken from a peripheral vein as part of clinical routine. Subsequently, a hormone status is determined.

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 35 Years

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64)

Sampling MethodNon-Probability Sample

Study Population

Patients with HH and secondary amenorrhea presenting to the Department of Obstetrics and Gynecology, Medical University of Vienna. The target number of cases for this pilot study is 50 patients.

You may qualify if:

Patient with HH and secondary amenorrhea. HH is defined as absence of spontaneous menstruation for ≥6 months, no abrupt menstrual bleeding after progesterone therapy, and normal or low serum FSH and LH levels.

Sponsors & Collaborators

Medical University of Vienna
Otherlead
Ferring Arzneimittel GmbH
Industrycollaborator

Study Sites (1)

Medical University of Vienna

Vienna, 1090, Austria

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples taken as part of routine clinical practice, including hormone status: AMH, FSH, LH, Estradiol, SHBG, DHEAS, Testosterone

MeSH Terms

Conditions

HypogonadismFollicular Cyst

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Gonadal DisordersEndocrine System DiseasesCystsNeoplasms

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, Operative

Study Officials

Johannes Ott, MD, PhD
Medical University of Vienna
PRINCIPAL INVESTIGATOR

Central Study Contacts

Johannes Ott, MD, PhD

CONTACT

+436504010485 johannes.ott@meduniwien.ac.at

Klara Beitl, MD

CONTACT

+4369912661163

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Associate Professor, Consultant Physician

Study Record Dates

First Submitted

May 31, 2021

First Posted

June 16, 2021

Study Start

April 2, 2023

Actual (reported)

Primary Completion

June 2024

Estimated (date passed)

Hormones in Hypogonadotropic Hypogonadism

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (2)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (2)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations